

7. Literaturverzeichnis

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *Journal of the National Cancer Institute* 1993; 85: 365-76

Abbruzzese JL, Rosenberg A et al. Phase II Study of anti-epidermal growth factor receptor cetuximab (IM-C225) in patients with advanced pancreatic cancer. *Proc Am Soc Clin Oncol* 2001; 20: 130a (abstr 518)

American Joint Committee on Cancer. *AJCC Cancer Staging Manual*. 5th ed. Philadelphia: Lippincott-Raven 1997

Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? *European Journal of Cancer* Mar 1998; 34(4): 503-09

Badia X, Schiaffino A, Alonso J et al. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. *Qual Life Res* 1998; 7: 311-22

Batel-Copel L, Kornblinth A, Batel P, Holland J. Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. *European Journal of Cancer* 1997; 33: 29-32

Batzler W, Bertz J, Eisinger B, Hentschel S, Husmann G, Kieschke J, Lehnert M, Oberhausen R, Schmidtman I, Schneider D. *Krebs in Deutschland Häufigkeiten und Trends*. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland in Zusammenarbeit mit dem Robert Koch Institut 2002: 32–35

Binstock M, Krakow D, Stamler J et al. Coffee and pancreatic cancer: an analysis of international mortality data. *Am J Epidemiol* 1983; 118: 630-36

Bob A, Bob K. Innere Medizin Duale Reihe Thieme-Verlag 2001: 1190-92

Bramhall SR. The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis. *Int J Pancreatol* 1998; 23: 83-100

Brooks R. EuroQol: the current state of play. *Health Policy* 1996; 37: 53-72

Burrish HA, Moore MJ et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; 14: 2403-13

Claes C, Greiner W, et al. An interview-based comparison of the TTO and VAS values given to EQ-5D states of health by the general German population. In: Greiner W, von der Schulenburg JM, Piercy J (Hrsg.). Plenary Meeting Hannover 1998, 1st-2nd October, Discussion papers. Hannover: Uni Verlag Witte, 1998: 13-38

Conner-Spady BL, Cumming C, Nabholz JM, Jacobs P, Stewart D. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. *Bone Marrow Transplantation* 2005; 36: 251-59

Conroy T, Paillot B, François E, Bugat R et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study. *J Clin Oncol* 2005; 23: 1228-36

Cull A, Sprangers M, Bjordal K, Aaronson N, West K, Bottomley A. EORTC QLQ-C30 Reference Values. Quality of Life Study Group 1998

Determann M, Kollenbaum V, Henne-Bruns D. Der Nutzen des Fragebogens zur Erfassung der Lebensqualität EORTC QLQ-C30 für die psychoonkologische Forschung. *Zentralbl Chir* 2004; 129: 14-17

Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997; 35: 1095-1108

Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic Cancer. *The Lancet* 2004; 363: 1049-57

Doorduijn J, Buijt I et al. Self reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. *Eur J Haematol* 2005; 75: 116-23

Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF. Cost analysis of pancreatic cancer treatment. *Cancer* 2000; 89: 1917-24.

Ekström K, Hoffman K, Linné T, Eriksson B, Glimelius B. Single-dose etoposide in advanced pancreatic and biliary cancer a phase II study. *Oncol Rep* 1998; 5: 931-34

Essink-Bot M, Krabbe P, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures. The Nottingham Health Profile the Medical Outcomes Study 36-item Short-Form Health Survey the COOP / WONCO charts and the EuroQol instrument. *Med Care* 1997; 35: 522-37

Faivre J, Forman D, Estève J, Obradovic M, Sant M, EUROCORE Working Group. Survival of patients with primary liver cancer pancreatic cancer and biliary tract cancer in Europe. *Eur J Cancer* 1998 ;34: 2184-90.

Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. *Eur J Cancer* 2001; 37: 1331-34

Fitzsimmons D et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire the QLQ-C30 in patients with pancreatic cancer. *European Journal of Cancer* Vol.35 Issue 1999; 6: 939-41

Fitzsimmons D, Johnson CD. Quality of life after treatment of pancreatic cancer. *Langenbecks Arch Surg.* 1998; 383(2): 145-51

Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni H. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. *Am J Epidemiol* 1988; 128: 324-330

Fischer F, Mirow L, Gondeck C, Schwandner O, Bruch H, Farke S. Einfluss der adjuvanten Radiochemotherapie beim Rektumkarzinom auf die Lebensqualität – Influence of Postoperative Radio-Chemotherapy for Rectal Cancer on Quality of life. *Z Gastroenterol* 2005; 43: 1213-18

François E, Hebbar M, Bennouna J et al. A phase II trial of Raltitrexed (Tomudex®) in advanced pancreatic and biliary carcinoma. *Oncology* 2005; 68: 299-305

Furuya N, Kawa S, Akamatsu T, Furihata K. Long-term follow-up of patients with chronic pancreatitis and K-ras mutation detected in pancreatic juice. *Gastroenterology* 1997; 113: 593-98

Fürst K. Pankreaskarzinom und Lebensqualität: welche Operation ist die beste? Ergebnisse eigener Untersuchungen zur Lebensqualität bei Pankreaskarzinom und periampullären Tumoren im internationalen Vergleich. Dissertation Bonn 1996: 10-12

Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. *Annals of Oncology* Aug 1996; 7(6): 593-600

Graf von der Schulenburg J, Claes C, Greiner W, Uber A. The German Version of the EuroQol Questionnaire. *Z. f. Gesundheitswiss.* 6. Jg. 1998: 3-20

Grahmann P, Crockett A. Self Assessment Quality of Life and Lung Diseases (SAQOL) in Patients with Pulmonary Carcinoma: Influence to Survival and Impact of Chronic Obstructive Pulmonary Disease. *Pneumologie* 2005; 59: 446-55

Greiner W, Claes C, Busschbach JJV, von der Schulenburg JM. Validating the EQ-5D with the time trade off for the German population. *European Journal of Health Economics* (2004) to be completed

Greiner W, Weijnen T et al. A single European currency for EQ-5D health states, Results from a six-country study. *European Journal of Health Economics* 2003; 4: 222-31

Halford S, Yip D, Karapetis CS, Strickland AH, Steger A, Khawaja HAT, Harper PG. A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin Doxil) in the treatment of unresectable pancreatic carcinoma. *Ann Oncol* 2001; 12: 1399-1402

Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Using reference data on quality of life – the importance of adjusting for age and gender exemplified by the EORTC QLQ-C30 (+3). *Eur J Cancer* 1998; 34: 1381-89

Holstege A, Schölmerich J. Das endoskopische Management von Pankreaserkrankungen. *Internist* 1996; 37: 800-16

Homs MYV, Essink-Bot ML, Borsboom GJJM, Steyerberg EW, Siersema PD. for the Dutch SIREC Study Group. Quality of life after palliative treatment for oesophageal carcinoma – a prospective comparison between stent placement and single dose brachytherapy. *Eur J Cancer* 2004 ; 40: 1862-71

Hopt UT, Brinckmann W. Pankreas-Karzinom: aktueller Stand von Diagnostik und Therapie. *WissenschaftsVerlag Weller* 2000: 1-3

Hürny C, Bernhard J, Laffer U, Dürig M. Tumorchirurgie und Lebensqualität: Ist Lebensqualität messbar? 1990: 1-10

Kaasa S, Loge JH. Quality-of-life assessment in palliative care. *Lancet Oncol* 2002; 3: 175-82

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481

Kelsen DP, Portenoy RK, Thaler HT, Niedzwiecki D, Passik SD, Tao Y, Banks W, Brennan MF, Foley KM. Pain and depression in patients with newly diagnosed pancreas cancer. Journal Clinical Oncology Mar 1995; 13(3): 748-55

Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. York Centre for Health Economics Discussion Paper 1999: 172

Kind P, Dolan P et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-41

Klee M, Groenvold M, Machin D. Quality of life of Danish women: population-based norms for the EORTC QLQ-C30. Qual Life Res 1997; 6: 27-34

Klinkenbijl JH, Jeekel J et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas and peri-ampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999; 230: 776-84

König HH, Bernert S, Angermeyer MC. Gesundheitszustand der deutschen Bevölkerung: Ergebnisse einer repräsentativen Befragung mit dem EuroQol-Instrument. Gesundheitswesen 2005; 67(3):173-82

Korfage IJ, Essink-Bot ML, Borsboom GJJM, Madalinska JB, Kirkels WJ, Habbema JDF, Schröder FH, de Koning HJ. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005; 116: 291-96

Küchler T, Drechsel-Atta H, Lucks M, Patzke R, Solecke U. Zur Lebensqualität von Krebspatienten im Verlauf der chirurgischen Akutbehandlung. Jahrbuch der medizinischen Psychologie Bd.3 Psychosoziale Onkologie Springer Verlag Berlin Heidelberg New York 1989: 169-79

Küchler T. Entwicklung der Lebensqualitätsmessung in der EORTC – der EORTC QLQ-C30. In: Schwarz R et al. Lebensqualität in der Onkologie II. München: W. Zuckerschwerdt 1995: 71-76

Küchler T, Rappat S, Holst K et al. Zum Einfluss psychosozialer Betreuung auf Lebensqualität und Überlebenszeit von Patienten mit gastrointestinalen Tumoren – eine prospektive randomisierte Studie. In: Koch U, Weis J (Hrsg.). Krankheitsverarbeitung bei Krebs und Möglichkeiten der Unterstützung. Schattauer Stuttgart 1998: 417-36

Kuvshinoff B, Bryer M. Treatment of Resectable and Locally Advanced Pancreatic Cancer. Cancer Control 2000; Vol.7 No. 5: 428-36

Langenhoff B, Krabbe P, Wobbes T, Ruers T. Quality of life as an outcome measure in surgical oncology. British Journal of Surgery 2001; 88 (5): 643-52

Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. European Journal of Cancer 1995; 31A: 882-87

Longo L. Harrisons Kompendium Innere Medizin: Hämatologie und Onkologie 2000: 387

Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. European Journal of Gastroenterology and Hepatology 1997; May,9(5): 481-84

Neoptolemos JP, Dunn JA, Stocken DD. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-85

Mack TM, Yu MC, Hanisch R, Henderson BEN. Pancreatic cancer and smoking beverage consumption and past medical history. J Natl Cancer 1986; 76: 49-53

Marczell A, Glaser K, Karner J, Mischinger H, Schratte-Sehn A, Tatzner G. Pankreaskarzinom und periampulläres Karzinom. ACO - Arbeitsgemeinschaft für Chirurgische Onkologie. ACO-Bulletin - Karzinome - Fakten und Statistik 1995

McLeod RS, Taylor BR, O'Connor BI, Greenberg GR, Jeejeebhoy KN, Royall D, Langer B. Quality of life nutritional status and gastrointestinal hormone profile following the Whipple procedure. American Journal of Surgery 1995; Jan, 169(1): 179-85

Moertel CG, Frytak S et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. Cancer 1981; 48: 1705-10

Müller-Nordhorn J, Brügggenjürgen B, Böhmig M, Selim D, Reich A, Noesselt L, Roll S, Wiedenmann B, Willich SN. Direct and indirect costs in a prospective cohort of patients with pancreatic cancer. Aliment Pharmacol Ther 2005;22:405-15

O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss appetite and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998; 32(2): 76-80

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the Significance of Changes in Health-Related Quality-of-Life Scores. Journal of Clinical Oncology 1998; Vol 16 No1: 139-44

Peto R, Peto J. Asymptotically efficient invariant test procedures. J R Stat Soc [A] 1972; 135: 185-206.

Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33: 337-43

Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? *Radiotherapy and Oncology* 2003; 76: 213-20

Ridder GJ, Klempnauer J. Back pain in patients with ductal pancreatic cancer. Its impact on resectability and prognosis after resection. *Scand J Gastroenterology* 1995; 30: 1216-220

Riede U, Schäfer H. *Allgemeine und spezielle Pathologie* Thieme-Verlag 2001
459-61

Rose MS, Koshman ML, Spreng S, Sheldon R. Statistical issues encountered in the comparison of health-related quality of life in diseased patients to published general population norms: problems and solutions. *J Clin Epidemiol* 1999; 52: 405-12

Ryan DP, Kulke MH et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. *Cancer* 2002; 94: 97-103

Safi F, Schlosser W, Falkenreck S, Berger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. *Hepatogastroenterology* 1998; 45: 253-59

Saltzburg D, Foley K. Management of pain in pancreatic cancer. *Surg Clin N Am* 1989; 69: 629-49

Schenk M, Schwartz AG, O'Neal E. Garabrant familial risk of pancreatic cancer. *J Natl Cancer Inst* 2001, 93: 640-44

Schipper H, Clinch J, Olweny C. *Quality of Life Studies: Definitions and Conceptual Issues. Quality of Life and Pharmacoeconomics in Clinical Trials.* Philadelphia Lippincott-Raven Publishers 1996 11-23

Schmier J, Elixhauser A, Halpern MT. Health-related quality of life evaluations of gastric and pancreatic cancer. *Hepatogastroenterology* 1999; 46: 1998-2004

Schwartz FW, Badura B, Leidl R, Raspe H, Siegrist J. Public Health – Gesundheit und Gesundheitswesen 1. Auflage 1998: 342-43 und 359-65

Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. European Journal of Cancer 2001; 37: 1345-1351

Statistisches Bundesamt Deutschland: Statistische Zeitreihe - Bevölkerung Soziales Preise Verdienste. Statis-Archiv-CD 1 2002

Svedlund J, Sjodin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-34

Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19: 855-63

UICC: TNM - Classification of Malignant Tumors revised edition 1992. Springer Berlin Heidelberg New York London 1992

Van den Hout WB, van der Linden YM, Steenland E, Wiggeraad RGJ, Kievit J, de Haes H, Leer JWH. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003; 95: 222-29

Wenger FA, Jacobi CA, Haubold K, Zieren HU, Müller JM. Gastrointestinale Lebensqualität nach Duodenopankreatektomie beim Pankreaskarzinom. Vorläufige Ergebnisse einer prospektiv-randomisierten Studie: PD vs. PPPD. Chirurg 1999; 70: 1454-59

West K. Translation Procedure and cross-cultural equivalence of EORTC instruments. EORTC – Quality of Life Group – Newsletter 2002; 2: 2-4

Wildi SM, Cox MH, Clark LL, Turner R, Hawes RH, Hoffman BJ, Wallace MB. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. *Am J Gastroenterol* 2004; 1044-49

Wolff RA, Evans DB et al. Initial results of preoperative gemcitabine-based chemoradiation for resectable pancreatic adenocarcinoma. *Proc Am Soc Clin Oncol* 2002; 21: 130a (abstr 516)

Zabora J, Brintzenhofesoc K, Curbow B, Hooker C, Piantadost S. The prevalence of psychological distress by cancer site. *Psycho-Oncology* 2001; 10: 19-28

